Skip to main content

Table 1 Basic information of the included patients

From: Thymalfasin therapy accelerates COVID-19 pneumonia rehabilitation through anti-inflammatory mechanisms

 

0 (n = 233)

1 (n = 105)

t/χ2

P

Gender (M/F)

128/105

61/44

0.178

0.67

Age (years)

77.6 ± 12.4

77.0 ± 9.21

0.46

0.64

WBC

6.12 ± 3.07

4.94 ± 2.14

4.07

< 0.01

LYM

0.86 ± 0.47

0.58 ± 0.27

6.85

< 0.01

CRP

59.8 ± 51.8

70.8 ± 45.69

-1.95

0.05

PCT

0.20 ± 0.48

0.20 ± 0.32

0.11

0.91

Fever (yes/no)

(180/53)

(84/21)

0.341

0.88

listlessness(yes/no)

(202/21)

(97/8)

0.21

0.57

Inflammatory exudate area shown on lung CT (%)

34.6 ± 12.3

33.8 ± 14.5

0.59

0.79

  1. 0: Thymalfasin group,1: control group,WBC the number of white blood cells and LYM lymphocyte: higher in Thymalfasin group than that in control group, CRP C-reactive protein: higher in Thymalfasin group than that in control group, PCT procalcitonin: no significant difference between the two groups